Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TP04HN106 in Amyotrophic Lateral Sclerosis
NCT06726577Phase 2Recruiting
- Sponsor
- Talengen Institute of Life Sciences
- Start
- Jun 2026
- Primary completion
- Jan 2027
- Countries
- 1
01
Overview
A Phase 2 trial of TP04HN106 in amyotrophic lateral sclerosis (ALS), sponsored by Talengen Institute of Life Sciences. Started Jun 2026; status: recruiting.
02
Drugs
TP04HN106
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT06726577.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06726577.